AI assistant
Chemomab Therapeutics Ltd. — Director's Dealing 2021
Mar 18, 2021
35107_dirs_2021-03-18_d963f8d1-5759-4d2b-9e49-00e93ffa7a67.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Chemomab Therapeutics Ltd. (CMMB)
CIK: 0001534248
Period of Report: 2021-03-16
Reporting Person: THIEL PETER (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-16 | American Depositary Shares | P | 230536 | — | Acquired | 1108509 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-16 | American Depositary Shares Purchase Warrant | $17.3509 | P | 23054 | Acquired | 2026-03-17 | American Depositary Shares (23054) | Indirect |
Footnotes
F1: The purchase reported herein was made in a private placement transaction entered into directly with the Issuer.
F2: Each American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares of the Issuer.
F3: Reported securities purchased in the private placement transaction as one ADS and one-tenth of one warrant (each whole warrant exercisable to purchase one ADS) for a combined price of $17.3509 per unit.
F4: These securities are held of record by Rivendell Investments 2017-9 LLC. The Reporting Person is the beneficial owner of Rivendell Investments 2017-9 LLC and has sole voting and investment power over the securities held by Rivendell Investments 2017-9 LLC.